V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10008363 | 10004884 | 1.77 | 80.9 | Palliative (P) | 2017-10-04 | 2017-10-04 | Bevacizumab+Carbo+Pacliaxel | 02 | N | 10489871 | ATG + BUSULFAN + FLUDARABINE |
| 10008364 | 10007462 | 1.76 | 86 | Palliative (P) | 2016-08-26 | 2016-08-26 | Cisplatin + Etoposide po&iv 3 day | N | N | 10489897 | CISPLATIN + RT |
| 10008365 | 10004888 | 1.7 | 78 | Palliative (P) | null | 2016-08-20 | Thalidomide 50mg | N | N | 10490318 | CETUXIMAB + IRINOTECAN + MDG |
| 10008366 | 10004890 | 1.8 | 101.7 | Palliative (P) | 2018-07-30 | 2018-07-30 | BORTEZOMIB + THALIDOMIDE | N | N | 10490760 | ENZALUTAMIDE |
| 10008367 | 10004892 | 1.6 | 81.5 | null | 2018-01-14 | 2018-01-14 | CHLVPP | N | N | 10490774 | ARSENIC TRIOXIDE + TRETINOIN |
| 10008368 | 10004894 | 1.74 | 81.9 | Palliative (P) | 2016-10-19 | 2016-10-19 | Erlotinib | 02 | N | 10490845 | AXITINIB |
| 10008369 | 10004895 | 1.64 | 91.1 | Palliative (P) | 2016-10-28 | 2016-10-29 | Cetuximab 14 day | 02 | N | 10490897 | BUSULPHAN |
| 10008370 | 10004897 | 1.72 | 80.6 | Adjuvant (A) | 2016-03-26 | 2016-04-08 | Cisplatin+Gemcitabine (gallbladder) | 02 | N | 10490921 | DOCETAXEL + NINTEDANIB |
| 10008371 | 10004901 | 1.71 | 74 | Neo-adjuvant (N) | 2017-05-02 | 2017-05-02 | Cisplatin + Gemcitabine (D 1 & 8) | 2 | N | 10491284 | ABVD |
| 10008372 | 10004903 | 1.7 | 0 | Palliative (P) | 2018-03-23 | 2018-03-24 | Alemtuz+Fludara+Melphalan RIC MUD | 02 | N | 10491336 | HYDROXYCARBAMIDE |
| 10008373 | 10004904 | 1.77 | 90.5 | Palliative (P) | 2017-10-09 | 2017-10-09 | Temozolomide + RT | 02 | N | 10491628 | PAZOPANIB |
| 10008374 | 10004906 | 1.66 | null | Palliative (P) | 2018-09-27 | 2018-10-08 | RUXOLITINIB | N | N | 10492449 | DOCETAXEL + TRASTUZUMAB |
| 10008375 | 10004908 | 1.83 | null | Palliative (P) | 2017-08-20 | 2017-08-23 | CAPECITABINE + CARBOPLATIN | 2 | Y | 10493601 | IDARUBICIN |
| 10008376 | 10004911 | 1.75 | 72.4 | Adjuvant (A) | 2017-07-22 | 2017-08-27 | VEDex | null | N | 10494098 | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL |
| 10008377 | 10008573 | 1.69 | null | Palliative (P) | 2017-07-18 | 2017-08-20 | Hydroxycarbamide | N | N | 10494453 | CETUXIMAB + IRINOTECAN + MDG |
| 10008378 | 10004912 | 1.72 | 56 | Palliative (P) | 2016-10-08 | 2016-10-18 | Temozolomide + RT | Y | N | 10494506 | AFATINIB |
| 10008379 | 10007474 | 1.73 | 0 | Palliative (P) | 2019-05-03 | 2019-05-10 | CHLVPP | 2 | N | 10494722 | CAPECITABINE + GEMCITABINE |
| 10008380 | 10004915 | 1.7 | 135.5 | Palliative (P) | 2014-10-17 | 2014-11-08 | Bortezomib +/- Dexamethasone | N | N | 10494795 | CABOZANTINIB |
| 10008381 | 10004918 | 1.54 | 63.2 | Palliative (P) | 2017-05-04 | 2017-05-04 | Irinotecan 14day | Y | N | 10495054 | IRINOTECAN |
| 10008382 | 10004919 | 1.83 | null | Curative (C) | 2017-08-24 | 2017-08-24 | Docetaxel + Nintedanib | 2 | N | 10495054 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 10008383 | 10004923 | 1.71 | 97 | Adjuvant (A) | 2014-05-01 | 2014-05-11 | IPILIMUMAB + NIVOLUMAB | N | N | 10496656 | IRINOTECAN |
| 10008384 | 10004926 | 1.78 | 69.5 | Palliative (P) | 2017-09-25 | 2017-09-25 | MaxiCHOP (>Cycle 2) | 02 | N | 10496956 | CRIZOTINIB |
| 10008385 | 10004928 | 1.58 | 0 | Palliative (P) | null | 2017-11-03 | EEF or EOF | 02 | N | 10496961 | CYCLOPHOSPHAMIDE + ETOPOSIDE + PROCARBAZINE |
| 10008386 | 10004929 | null | 76 | Adjuvant (A) | 2017-09-24 | 2017-10-28 | POMALIDOMIDE | 2 | N | 10498010 | CISPLATIN + GEMCITABINE |
| 10008387 | 10004931 | null | 78 | Palliative (P) | 2018-08-31 | 2018-09-01 | VEDex | N | N | 10498592 | FEC + TRASTUZUMAB |
| 10008388 | 10004933 | 1.73 | 83.2 | Curative (C) | 2017-12-10 | 2017-12-17 | EOX | N | N | 10498611 | TEMOZOLOMIDE + RT |
| 10008389 | 10004934 | 1.8 | 111 | Palliative (P) | 2019-03-21 | 2019-03-21 | CYCLOPHOSPHAMIDE + RITUXIMAB + Dexamethasone | N | N | 10498761 | ERLOTINIB |
| 10008390 | 10004935 | 1.68 | 70 | Palliative (P) | 2016-12-31 | 2017-08-25 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | 10499282 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 10008391 | 10004939 | 1.58 | 60.7 | Adjuvant (A) | null | 2019-03-22 | FEC + DOCETAXEL + TRASTUZUMAB | N | N | 10501772 | CISPLATIN + VINORELBINE |
| 10008392 | 10004941 | 1.72 | null | Palliative (P) | 2017-12-26 | 2018-01-03 | CYCLOPHOSPHAMIDE + ETOPOSIDE + LOMUSTINE | null | null | 10502066 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10008393 | 10004945 | 1.7 | 75.5 | Palliative (P) | 2018-03-02 | 2018-03-13 | CETUXIMAB + IRINOTECAN + MDG | 2 | N | 10502117 | IRINOTECAN |
| 10008394 | 10004948 | 1.8 | 79.3 | null | 2015-01-29 | 2015-02-01 | Cisplatin+Gemcitabine (gallbladder) | N | N | 10502260 | FLAG + IDARUBICIN |
| 10008395 | 10004950 | 1.7 | 79.3 | Radical (R) | 2016-08-20 | 2016-09-16 | DABRAFENIB + TRAMETINIB | N | null | 10502333 | ETOPOSIDE |
| 10008396 | 10008581 | 1.84 | 106.6 | Palliative (P) | 2018-06-05 | 2018-07-05 | MaxiCHOP (>Cycle 2) | N | N | 10502596 | MPV |
| 10008397 | 10004952 | 1.49 | 50.9 | Disease modification (D) | 2018-06-13 | 2018-09-12 | Docetaxel + Nintedanib | N | N | 10502964 | PCV |
| 10008398 | 10004955 | 1.65 | 110 | Adjuvant (A) | 2016-12-17 | 2016-12-23 | PLATFORM Trial + MEDI4736 | N | N | 10503009 | CAPECITABINE + CISPLATIN |
| 10008399 | 10007493 | 1.73 | 96.2 | Palliative (P) | 2018-01-24 | 2018-02-15 | DA-EPOCH-R | N | N | 10504071 | METHOTREXATE INTRATHECAL |
| 10008400 | 10004962 | 1.58 | null | Disease modification (D) | 2015-11-06 | 2015-11-09 | CYCLOPHOSPHAMIDE + EPIRUBICIN | N | N | 10504251 | FEC + DOCETAXEL |
| 10008401 | 10004965 | 1.64 | null | Palliative (P) | 2018-07-17 | 2018-07-22 | Cape+Cisplatin+Trastuzumab Main | N | N | 10504301 | CAPECITABINE + IRINOTECAN |
| 10008402 | 10004967 | 1.7 | 57.5 | Curative (C) | 2018-01-30 | 2018-02-21 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | 10504393 | BORTEZOMIB |
| 10008403 | 10007498 | 1.78 | 106.6 | Disease modification (D) | 2018-04-01 | 2018-06-24 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | 2 | N | 10504440 | RCEOP |
| 10008404 | 10004970 | 1.76 | 57 | Not known (9) | 2018-01-26 | 2018-01-28 | Ipilimumab | 2 | N | 10504736 | RUXOLITINIB |
| 10008405 | 10004974 | null | 93 | Adjuvant (A) | 2017-02-01 | 2017-02-05 | CISPLATIN + VINORELBINE | 02 | Y | 10505533 | FEC |
| 10008406 | 10004977 | 1.64 | null | Adjuvant (A) | 2018-08-25 | 2018-08-31 | DABRAFENIB | N | N | 10505550 | BORTEZOMIB + PANOBINOSTAT |
| 10008407 | 10004977 | 1.62 | null | Curative (C) | 2017-06-08 | 2017-06-29 | Cisplatin 100 + RT(H&N) 1 day | 02 | n | 10505550 | DA |
| 10008408 | 10004979 | 1.9 | 85.3 | Palliative (P) | 2015-02-22 | 2015-03-07 | Bexarotene | 02 | N | 10505773 | CISPLATIN + GEMCITABINE |
| 10008409 | 10004981 | 1.7 | 82.9 | Palliative (P) | 2019-03-14 | 2019-04-16 | CETUXIMAB + IRINOTECAN + MDG | N | N | 10505847 | CERITINIB |
| 10008410 | 10004982 | 1.58 | 72 | Palliative (P) | 2018-04-13 | 2018-04-20 | GEFITINIB | N | N | 10505847 | DOCETAXEL + NINTEDANIB |
| 10008411 | 10004984 | 1.64 | 61 | Curative (C) | 2018-11-28 | 2018-12-12 | FEC 100 | N | N | 10506303 | LANREOTIDE |
| 10008412 | 10007507 | 1.67 | 101.85 | Palliative (P) | 2015-08-01 | 2015-08-13 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | N | N | 10506435 | GEMCARBO + RITUXIMAB |